Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Ankyrin repeat and ubiquitin domain-containing protein 1 (ANKUB1), also known as C3orf16, is a human protein characterized by the presence of three ankyrin repeat domains, a ubiquitin domain, and a low complexity region[1][3][9][11]. Ankyrin repeats are structural motifs known to mediate protein–protein interactions, while the ubiquitin domain is associated with protein turnover and signaling, typically through interactions involved in ubiquitinylation[1][9]. ANKUB1 is not currently established as a classical therapeutic target such as a receptor, ion channel, or enzyme, and there are no known drugs or targeted therapies against it[11][13]. Frameshift mutations in ANKUB1 have been observed in rare cases of familial polysyndactyly (PSD), implicating possible functions in developmental processes, though the exact biological role remains to be validated[1]. Data suggest that ANKUB1 might act in protein regulation or cellular signaling pathways; however, its precise physiological or pathological roles remain largely uncharacterized, and it is not widely recognized as a disease gene or biomarker[1][11][13].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ankyrin repeat and ubiquitin domain-containing protein 1 (ANKUB1).